Advanced in Posterior Fossa Tumor

Dr. Antonios I. Christou

Oncology | Hematology
Allegheny Clinic Medical Oncology
1 Nolte Dr, 
Kittanning, PA 
Accepting New Patients
Advanced in Posterior Fossa Tumor
Allegheny Clinic Medical Oncology
1 Nolte Dr, 
Kittanning, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Antonios Christou is an Oncologist and a Hematologist in Kittanning, Pennsylvania. Dr. Christou is rated as an Advanced provider by MediFind in the treatment of Posterior Fossa Tumor. His top areas of expertise are Angiosarcoma, Lung Cancer, Inflammatory Breast Cancer, and Small Cell Lung Cancer (SCLC). Dr. Christou is currently accepting new patients.

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in PA
Hospital Affiliations
Allegheny Valley Hospital
Allegheny General Hospital
West Penn Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

ALLEGHENY CLINIC MEDICAL ONCOLOGY
1 Nolte Dr, Kittanning, PA 16201
Other Locations
ALLEGHENY CLINIC MEDICAL ONCOLOGY
1301 Carlisle St, Natrona Heights, PA 15065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor
Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Fulvestrant
Study Phase: Phase 2
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Other, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological, Other
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)
Enrollment Status: Completed
Publish Date: June 01, 2023
Intervention Type: Biological, Drug, Other
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: June 23, 2021
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)
Enrollment Status: Completed
Publish Date: May 27, 2021
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Palbociclib
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

10 Total Publications

Unusual polarimetric properties for interstellar comet 2I/Borisov.
Unusual polarimetric properties for interstellar comet 2I/Borisov.
Journal: Nature communications
Published: October 28, 2020
Similar Doctors
Distinguished in Posterior Fossa Tumor
Dr. Shannon L. Huggins-Puhalla
Oncology
Distinguished in Posterior Fossa Tumor
Dr. Shannon L. Huggins-Puhalla
Oncology

Oncology Hematology Association Inc

5115 Centre Ave, Fl 3, 
Pittsburgh, PA 
 (31.5 miles away)
412-235-1020
Languages Spoken:
English
See accepted insurances

Shannon Huggins-Puhalla is an Oncologist in Pittsburgh, Pennsylvania. Dr. Huggins-Puhalla is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Angiosarcoma.

Jaime A. Mullin
Distinguished in Posterior Fossa Tumor
Dr. Jaime A. Mullin
Oncology
Distinguished in Posterior Fossa Tumor
Dr. Jaime A. Mullin
Oncology

UPMC Hillman Cancer Center

5115 Centre Avenue, Floor 3, 
Pittsburgh, PA 
 (31.3 miles away)
412-755-2753
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jaime Mullin, DO, is a medical oncologist at UPMC Hillman Cancer Center. Dr. Mullin is rated as an Advanced provider by MediFind in the treatment of Posterior Fossa Tumor. Her top areas of expertise are Small Cell Lung Cancer (SCLC), Posterior Fossa Tumor, Pleuropulmonary Blastoma, Gamma Knife Radiosurgery, and Gastrostomy.

Distinguished in Posterior Fossa Tumor
Dr. Leonard J. Appleman
Hematology Oncology | Oncology | Hematology
Distinguished in Posterior Fossa Tumor
Dr. Leonard J. Appleman
Hematology Oncology | Oncology | Hematology

University Of Pittsburgh Physicians

5115 Centre Ave, 
Pittsburgh, PA 
 (31.5 miles away)
412-692-4724
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leonard Appleman is a Hematologist Oncology specialist and an Oncologist in Pittsburgh, Pennsylvania. Dr. Appleman is rated as a Distinguished provider by MediFind in the treatment of Posterior Fossa Tumor. His top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, and Chromophobe Renal Cell Carcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Christou's expertise for a condition
ConditionClose
    View All 17 Advanced Conditions
    View All 70 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile